Communiqués Amgen Inc. Xetra

Actions

AMG

US0311621009

Produits pharmaceutiques

Temps réel estimé Tradegate 17:30:18 30/09/2026			Varia. 5j.	Varia. 1 janv.
373,78 ^EUR	+1,61%		+4,75%	+33,43%

16:46	Les développeurs de traitements amaigrissants se bousculent pour conquérir un marché lucratif où la concurrence s’intensifie	RE
28/09	Amgen Inc. : Scotiabank maintient sa recommandation à l'achat	ZM

Communiqués

23/09	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJOGREN'S DISEASE	AQ
22/09	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE	PR
14/09	FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®	PR
10/09	FTC Updates (August 17-21, 24-28)	AQ
09/09	AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	PR
08/09	IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER	PR
07/09	Filed, Not Forgotten: FTC Signals Antitrust Scrutiny Of Patent Application Acquisitions In Biologic Drug Markets	AQ
02/09	AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE	PR
31/08	AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE	PR
28/08	AstraZeneca - Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	AQ
27/08	TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS	PR
04/08	Amgen: Q2 Earnings Snapshot	AQ
04/08	AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS	PR
30/07	AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND	PR
29/07	Amgen : POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE	PU
28/07	AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS	PR
27/07	Protecting Antibody Innovations Beyond Composition Claims	AQ
24/07	Amgen : Statement on FDA Data Submission for TAVNEOS® (avacopan)	PU
08/07	Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech	PU
22/06	Amgen : What a Landmark Real-World Study Reveals About Thyroid Eye Disease	PU
07/06	AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS	PR
04/06	AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	PR
04/06	Bob Bradway on AI: Reimagining the Future of Biotechnology	PU
03/06	AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026	PR
01/06	Amgen : EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER	PU